- Home
- GDEN vs CVAC Comparison
GDEN vs CVAC Comparison
Compare GDEN & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- CVAC
- Stock Information
- Founded
- GDEN 1998
- CVAC 2000
- Country
- GDEN United States
- CVAC Germany
- Employees
- GDEN N/A
- CVAC N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- CVAC Health Care
- Exchange
- GDEN Nasdaq
- CVAC Nasdaq
- Market Cap
- GDEN 705.7M
- CVAC 818.8M
- IPO Year
- GDEN 1999
- CVAC 2020
- Fundamental
- Price
- GDEN $27.32
- CVAC $3.47
- Analyst Decision
- GDEN Strong Buy
- CVAC Strong Buy
- Analyst Count
- GDEN 7
- CVAC 2
- Target Price
- GDEN $36.86
- CVAC $14.00
- AVG Volume (30 Days)
- GDEN 152.9K
- CVAC 535.9K
- Earning Date
- GDEN 05-08-2025
- CVAC 05-22-2025
- Dividend Yield
- GDEN 3.85%
- CVAC N/A
- EPS Growth
- GDEN N/A
- CVAC N/A
- EPS
- GDEN 0.39
- CVAC 0.75
- Revenue
- GDEN $653,614,000.00
- CVAC $554,073,921.00
- Revenue This Year
- GDEN $2.32
- CVAC N/A
- Revenue Next Year
- GDEN $2.80
- CVAC $38.07
- P/E Ratio
- GDEN $66.78
- CVAC $4.65
- Revenue Growth
- GDEN N/A
- CVAC 895.54
- 52 Week Low
- GDEN $22.66
- CVAC $2.22
- 52 Week High
- GDEN $35.49
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- GDEN 58.80
- CVAC 56.52
- Support Level
- GDEN $25.28
- CVAC $3.26
- Resistance Level
- GDEN $26.67
- CVAC $3.63
- Average True Range (ATR)
- GDEN 0.85
- CVAC 0.21
- MACD
- GDEN 0.20
- CVAC 0.01
- Stochastic Oscillator
- GDEN 83.40
- CVAC 51.83
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.